Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial

Peer Review reports

Original Submission
23 Mar 2020	Submitted	Original manuscript
2 Jun 2020	Reviewed	Reviewer Report
20 Jul 2020	Reviewed	Reviewer Report
1 Aug 2020	Author responded	Author comments - Chris Dickhoff
Resubmission - Version 2
1 Aug 2020	Submitted	Manuscript version 2
Publishing
5 Aug 2020	Editorially accepted
14 Aug 2020	Article published	10.1186/s12885-020-07263-9

Back to article page